These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28943101)

  • 1. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
    Meshram DD; Pike CVS; Coussons PJ
    Eur J Pharmacol; 2017 Nov; 815():332-342. PubMed ID: 28943101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
    Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
    Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
    Agnihotri N; Mehta K
    Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
    Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
    Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis.
    Jang JH; Park JS; Lee TJ; Kwon TK
    Cancer Lett; 2010 Jan; 287(2):224-30. PubMed ID: 19632032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gα(h)/transglutaminase-2 activity is required for maximal activation of adenylylcyclase 8 in human and rat glioma cells.
    Obara Y; Yanagihata Y; Abe T; Dafik L; Ishii K; Nakahata N
    Cell Signal; 2013 Mar; 25(3):589-97. PubMed ID: 23200849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells.
    Shrestha R; Tatsukawa H; Shrestha R; Ishibashi N; Matsuura T; Kagechika H; Kose S; Hitomi K; Imamoto N; Kojima S
    Cell Death Dis; 2015 Dec; 6(12):e2002. PubMed ID: 26633708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of transglutaminase 2 in PAC
    Algarni AS; Hargreaves AJ; Dickenson JM
    Biochem Pharmacol; 2017 Mar; 128():55-73. PubMed ID: 28065858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of tissue transglutaminase expression in malignant melanoma.
    Fok JY; Ekmekcioglu S; Mehta K
    Mol Cancer Ther; 2006 Jun; 5(6):1493-503. PubMed ID: 16818508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of TG2 in regulating S100A4-mediated mammary tumour cell migration.
    Wang Z; Griffin M
    PLoS One; 2013; 8(3):e57017. PubMed ID: 23469180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
    Liu T; Tee AE; Porro A; Smith SA; Dwarte T; Liu PY; Iraci N; Sekyere E; Haber M; Norris MD; Diolaiti D; Della Valle G; Perini G; Marshall GM
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18682-7. PubMed ID: 18003922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β
    Vyas FS; Nelson CP; Freeman F; Boocock DJ; Hargreaves AJ; Dickenson JM
    Eur J Pharmacol; 2017 Oct; 813():105-121. PubMed ID: 28754379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
    Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
    Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
    [No Abstract]   [Full Text] [Related]  

  • 16. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
    Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
    Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A1 adenosine receptor-induced phosphorylation and modulation of transglutaminase 2 activity in H9c2 cells: A role in cell survival.
    Vyas FS; Hargreaves AJ; Bonner PL; Boocock DJ; Coveney C; Dickenson JM
    Biochem Pharmacol; 2016 May; 107():41-58. PubMed ID: 27005940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells.
    Dong X; Liu F; Li M
    Anticancer Drugs; 2016 Apr; 27(4):286-99. PubMed ID: 26704389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.
    Cao L; Petrusca DN; Satpathy M; Nakshatri H; Petrache I; Matei D
    Carcinogenesis; 2008 Oct; 29(10):1893-900. PubMed ID: 18667446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complex role of transglutaminase 2 in glioblastoma proliferation.
    Gundemir S; Monteagudo A; Akbar A; Keillor JW; Johnson GVW
    Neuro Oncol; 2017 Feb; 19(2):208-218. PubMed ID: 27591334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.